{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T18:48:17Z","timestamp":1775846897868,"version":"3.50.1"},"reference-count":20,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"unspecified","delay-in-days":9,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Fund for Scientific Research -Flanders","award":["G083621N"],"award-info":[{"award-number":["G083621N"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2026,3,17]]},"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>In a fraction of patients with rheumatoid arthritis (RA), antinuclear antibodies (ANA) are present. However, in most ANA-positive samples from patients with RA, no autoantigens can be identified. We aimed to characterise the ANA landscape in RA and to identify known and novel autoantigens using an unbiased immunoprecipitation-mass spectrometry (IP-MS) approach.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Sera from 51 ANA-positive, DMARD-na\u00efve patients with RA were analysed by IP-MS using HeLa nuclear or cytoplasmic extracts (depending on the ANA staining pattern). Immunoprecipitated proteins were digested and identified using liquid chromatography coupled with MS. The prevalence of new or unfamiliar autoantigens was assessed in 43 healthy individuals and 88 ANA-positive individuals with a systemic rheumatic disease (systemic lupus erythematosus, Sj\u00f6gren\u2019s disease, systemic sclerosis and idiopathic inflammatory myopathy).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Autoantigens were detected in 10 of 51 RA samples (in 2\/29 with titre 1\/160, in 4\/12 with titre 1\/320 and in 4\/10 with titre \u22651\/640). Autoantigens identified included SSA-Ro60, SSB-La, Ku, fibrillarin, components of the mitochondrial multienzyme complex, protein argonaute 1, 2, 3 and T-cell restricted intracellular antigen 1 and TIA-1-related protein. Two novel autoantigens were discovered: the N-terminal acetyltransferase C (NatC) complex and mitochondrial chaperone BCS1. Neither NatC nor BCS1 was detected in healthy individuals or individuals with other systemic rheumatic diseases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>IP-MS revealed a diverse spectrum of autoantigens in patients with ANA-positive RA, including previously unreported targets. These findings expand our knowledge of RA-associated autoimmunity and highlight antibodies to NatC and BCS1 as potential novel biomarkers. Further studies are needed to assess their clinical relevance.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/rmdopen-2025-006642","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T17:50:14Z","timestamp":1775843414000},"page":"e006642","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Immunoprecipitation-mass spectrometry reveals known and novel (NatC,\n                    <i>BCS1L<\/i>\n                    ) antinuclear antibodies in rheumatoid arthritis"],"prefix":"10.1136","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6153-3140","authenticated-orcid":false,"given":"Jonas","family":"De Leeuw","sequence":"first","affiliation":[{"name":"Department of Microbiology, Immunology and Transplantation, Clinical and Diagnostic Immunology, KU Leuven, Leuven, Belgium"},{"name":"Department of Rheumatology, University Hospitals Leuven, Leuven, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Birthe","family":"Michiels","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Immunology and Transplantation, Clinical and Diagnostic Immunology, KU Leuven, Leuven, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rita","family":"Derua","sequence":"additional","affiliation":[{"name":"Laboratory for Protein Phosphorylation and Proteomics, KU Leuven, Leuven, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Baptiste","family":"Vulsteke","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Immunology and Transplantation, Clinical and Diagnostic Immunology, KU Leuven, Leuven, Belgium"},{"name":"Department of Rheumatology, University Hospitals Leuven, Leuven, Belgium"},{"name":"Department of Rheumatology, AZ Delta, Roeselare, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Doreen","family":"Dillaerts","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Immunology and Transplantation, Clinical and Diagnostic Immunology, KU Leuven, Leuven, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maaike","family":"Cockx","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Immunology and Transplantation, Clinical and Diagnostic Immunology, KU Leuven, Leuven, Belgium"},{"name":"PharmAbs, The KU Leuven Antibody Center, Leuven, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0340-3580","authenticated-orcid":false,"given":"Patrick","family":"Verschueren","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, University Hospitals Leuven, Leuven, Belgium"},{"name":"Department of Development and Regeneration, Skeletal Biology and Engineering Research Centre, KU Leuven, Leuven, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6856-8485","authenticated-orcid":false,"given":"Xavier","family":"Bossuyt","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Immunology and Transplantation, Clinical and Diagnostic Immunology, KU Leuven, Leuven, Belgium"},{"name":"PharmAbs, The KU Leuven Antibody Center, Leuven, Belgium"},{"name":"Department of Laboratory Medicine, University Hospitals Leuven, Leuven, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2026,4,10]]},"reference":[{"key":"2026041010500820000_12.2.e006642.1","doi-asserted-by":"crossref","first-page":"1358114","DOI":"10.3389\/fimmu.2024.1358114","article-title":"Association between serum antinuclear antibody and rheumatoid arthritis","volume":"15","author":"Liu","year":"2024","journal-title":"Front Immunol"},{"key":"2026041010500820000_12.2.e006642.2","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/acr2.11271","article-title":"Exploring the role of antinuclear antibody positivity in the diagnosis, treatment, and health outcomes of patients with rheumatoid arthritis","volume":"3","author":"Paknikar","year":"2021","journal-title":"ACR Open Rheumatol"},{"key":"2026041010500820000_12.2.e006642.3","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.ard.2025.05.008","article-title":"The TFIID complex is a new autoantibody target in systemic sclerosis","volume":"85","author":"Vulsteke","year":"2026","journal-title":"Ann Rheum Dis"},{"key":"2026041010500820000_12.2.e006642.4","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-222686"},{"key":"2026041010500820000_12.2.e006642.5","doi-asserted-by":"crossref","first-page":"e216","DOI":"10.1093\/rheumatology\/kead060","article-title":"Detection of anti-eIF2B autoantibodies in systemic sclerosis by immunoprecipitation-mass spectrometry","volume":"62","author":"Vulsteke","year":"2023","journal-title":"Rheumatology (Sunnyvale)"},{"key":"2026041010500820000_12.2.e006642.6","doi-asserted-by":"crossref","first-page":"102988","DOI":"10.1016\/j.jaut.2022.102988","article-title":"Identification of new telomere- and telomerase-associated autoantigens in systemic sclerosis","volume":"135","author":"Vulsteke","year":"2023","journal-title":"J Autoimmun"},{"key":"2026041010500820000_12.2.e006642.7","doi-asserted-by":"crossref","first-page":"103288","DOI":"10.1016\/j.autrev.2023.103288","article-title":"Antinuclear antibodies in individuals with COVID-19 reflect underlying disease: identification of new autoantibodies in systemic sclerosis (CDK9) and malignancy (RNF20, RCC1, TRIP13)","volume":"22","author":"Bossuyt","year":"2023","journal-title":"Autoimmun Rev"},{"key":"2026041010500820000_12.2.e006642.8","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez213"},{"key":"2026041010500820000_12.2.e006642.9","doi-asserted-by":"crossref","first-page":"119928","DOI":"10.1016\/j.cca.2024.119928","article-title":"Integrating pretest probability for rheumatoid arthritis with likelihood ratios of RF and ACPA to improve clinical utility of rheumatoid arthritis autoantibody testing","volume":"564","author":"Vandebeek","year":"2025","journal-title":"Clin Chim Acta"},{"key":"2026041010500820000_12.2.e006642.10","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.138461"},{"key":"2026041010500820000_12.2.e006642.11","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2004.035964"},{"key":"2026041010500820000_12.2.e006642.12","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/606195","article-title":"Clinical and pathological roles of Ro\/SSA autoantibody system","volume":"2012","author":"Yoshimi","year":"2012","journal-title":"Clin Dev Immunol"},{"key":"2026041010500820000_12.2.e006642.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2010.05.020"},{"key":"2026041010500820000_12.2.e006642.14","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/40.10.1157"},{"key":"2026041010500820000_12.2.e006642.15","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4614-5107-5_4"},{"key":"2026041010500820000_12.2.e006642.16","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200105","article-title":"Anti-AGO1 antibodies identify a subset of autoimmune sensory neuronopathy","volume":"10","author":"Moritz","year":"2023","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2026041010500820000_12.2.e006642.17","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkae1010"},{"key":"2026041010500820000_12.2.e006642.18","doi-asserted-by":"publisher","DOI":"10.1002\/art.23435"},{"key":"2026041010500820000_12.2.e006642.19","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1002\/art.42729","article-title":"The limitation of flowcytometry is ignored in the assessment of antimitochondrial antibodies in rheumatoid arthritis: comment on the article by Moore et al","volume":"76","author":"Jearn","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"2026041010500820000_12.2.e006642.20","doi-asserted-by":"publisher","DOI":"10.1038\/ng706"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2025-006642","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T17:50:16Z","timestamp":1775843416000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2025-006642"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":20,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,4,10]]},"published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1136\/rmdopen-2025-006642"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2025-006642","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4]]}}}